• Robert H Dworkin, Dennis C Turk, Jeremiah J Trudeau, Carmela Benson, David M Biondi, Nathaniel P Katz, and Myoung Kim.
• Department of Anesthesiology, University of Rochester School of Medicine and Dentistry, Rochester, New York; Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York; Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry, Rochester, New York. Electronic address: robert_dworkin@urmc.rochester.edu.
• J Pain. 2015 Apr 1;16(4):357-66.

UnlabelledThe Short-form McGill Pain Questionnaire (SF-MPQ-2) assesses the major symptoms of both neuropathic and nonneuropathic pain and can be used in studies of epidemiology, natural history, pathophysiologic mechanisms, and treatment response. Previous research has demonstrated its reliability, validity, and responsiveness in diverse samples of patients with chronic pain. However, the SF-MPQ-2 has not been evaluated for use in patients with acute pain. Data were examined from a double-blind, randomized clinical trial of immediate-release tapentadol versus immediate-release oxycodone in patients with acute low back and associated radicular leg pain (N = 666). Analyses of internal consistency, convergent validity, and confirmatory factor structure were conducted using baseline data, and analyses of responsiveness were conducted using baseline and endpoint data. The SF-MPQ-2 total score and its 4 subscale scores (continuous pain, intermittent pain, predominantly neuropathic pain, and affective descriptors) generally showed good psychometric properties and 1) were internally consistent, 2) displayed good convergent validity, 3) fit the a priori factor structure, and 4) were highly responsive to analgesic treatment. These data extend previous evidence of the reliability, validity, and responsiveness of the SF-MPQ-2 in patients with chronic pain to those with acute low back and associated radicular leg pain.PerspectiveConsidered together with the results of other recent studies, the data suggest that the SF-MPQ-2 can provide a valid, responsive, and efficient assessment of both neuropathic and nonneuropathic pain qualities for clinical trials and other clinical research examining patients with various acute and chronic pain conditions.Copyright © 2015 American Pain Society. Published by Elsevier Inc. All rights reserved.

34 keywords...

hide…